CASI — CASI Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $85.10m
- $90.05m
- $33.88m
- 46
- 16
- 96
- 52
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 54.2 | 66.4 | 48.6 | 49.9 | 18.8 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.29 | 4.64 | 9.8 | 13 | 10.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 61.5 | 74 | 62 | 73.4 | 59.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9.69 | 10.8 | 21.8 | 13.2 | 11.6 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 103 | 128 | 138 | 96.2 | 75.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7.95 | 7.98 | 13.2 | 17 | 16.7 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 29.6 | 46.2 | 53.8 | 51.7 | 51.1 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 73 | 81.5 | 84.5 | 44.6 | 24.2 |
Total Liabilities & Shareholders' Equity | 103 | 128 | 138 | 96.2 | 75.3 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |